Drugs Information:
Natalizumab
Basic Information
|
||
| ID | DDInter1268 | |
| Drug Type | biotech | |
| Protein Chemical Formula | None | |
| Protein Average Weight | - | |
| CAS Number | 189261-10-7 | |
| Description | Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006. | |
| ATC Classification | L04AA23 | |
| Sequences | None | |
| Useful Links | DrugBank PubChem Substance PharmGKB Therapeutic Targets Database Wikipedia ChEMBL | |
Interactions with
Natalizumab
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|